Like Biodefense Stocks? View our Biodefense Stocks Directory
Aethlon Medical, Inc. (OTCQB:AMED) creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. www.aethlonmedical.com
Research and Markets: Fingerprint Biometrics - Global Strategic Business Report 2015 with Recent Industry Activity for All Key Players
View Systems, Inc. (VSYM) Continues Nationwide Installation of its Weapons Detection Technology
Biometrics to become the predominant method to identify bank customers by 2020
Breaking Tech News: NXT-ID, Inc. (Nasdaq:NXTD; NXTDW) to Air New Video on CNBC in New York Markets
Breaking Tech News: NXT-ID, Inc. (Nasdaq:NXTD; NXTDW) Announces Participation as Member of Team Battelle for TIES Contract Award
Breaking Tech News: NXT-ID, Inc.'s (NASDAQ:NXTD) (NXTDW) CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC.
/C O R R E C T I O N -- NXT-ID, Inc. (NASDAQ:NXTD) /
NXT-ID, Inc. (NASDAQ:NXTD) Announces Strategic Partnership With Wallaby Financial; Wallaby Members Offered NXT-ID's Wocket Smart Wallet as an All-in-One Card Secure, Convenient Payment Solution
NXT-ID (NASDAQ:NXTD) Media Alert; SlashGear and Credit Union Times Cover Shipment of Wocket to Pre-Order Customers
Breaking Tech News: Wocket, the Smartest Wallet (Nasdaq:NXTD; NXTDW) You Will Ever Own, Announces Shipment to Pre-order Customers
Luminex Receives $17.40 Average Price Target from Brokerages (NASDAQ ...
Dakota Financial News
Luminex logo Shares of Luminex (NASDAQ:LMNX) have received an average recommendation of “Hold” from the eight brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, ... The ...
Ronald Richard just Sold 4923 shares of Emergent Biosolutions Inc (NYSE:EBS ...
A public form filed with the Washington-based SEC on July 1, 2015 disclosed that Ronald Richard, the director of Emergent Biosolutions Inc (NYSE:EBS) 32.36 -0.96 -2.88% , professional & scientific & and technical services's company sold 4,923 shares.
Soligenix Inc (OTCBB:SNGX) Hits New Highs
This continues the run the stock made recently off its base at $1. SNGX is a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. SNGX has two distinctive ...
News Review - Soligenix (SNGX), Anglo American (AAUKY), CGrowth Capital ...
Aeolus Pharmaceuticals, Inc ( OTC:AOLS ) is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology.
Aethlon Medical, Inc. ( OTCBB: AEMD ) Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression.
Alexium International Group ( ASX:AJX.AX ) is engaged in developing and licensing its intellectual property, Reactive Surface Treatment (RST) technology. Alexium is focused on developing the RST technology for a range of military and commercial applications. Alexium’s Reactive Surface Treatment (RST) is a technology for nanoscopic coatings that combines advanced materials chemistry with a processing step. Alexium’s Reactive Surface Treatment (RST) uses cold microwave energy to direct a precursor’s polymerization onto a substrate’s surface. Its technology is used in textiles, air/fluid filtration, industrial coatings, composite fibers, leather, glass/lens surface treatment, bulk chemicals and thin films. BIODEFENSE: Responding to specific military and first responder needs, Alexium developed the Cleanshell® chemistry to offer a new generation of liquid repellency protection in chemical and biological threat scenarios. Cleanshell® CB is an advanced repellency treatment, optimized for chemical and biological protection. Cleanshell® CB has been optimized to provide excellent water and oil repellency, but has also dramatically increased the repellency of Chemical Warfare Agent (CWA) simulants. Cleanshell® CB offers days of protection versus minutes for conventional fluorocarbon repellency finishes.
American Science and Engineering, Inc ( NasdaqGS: ASEI ) is a leading worldwide supplier of innovative X-ray inspection systems. With over 50 years of experience in developing advanced X-ray security systems, the Company's product line utilizes a combination of technologies, including patented Z Backscatter™ technology, Radioactive Threat Detection (RTD), high energy transmission and dual energy transmission X-ray. These technologies offer superior X-ray threat detection for plastic explosives, plastic weapons, liquid explosives, dirty bombs and nuclear devices. AS&E's complete range of products include cargo inspection systems for port and border security baggage screening systems for facility and aviation security, and personnel and passenger screening systems. AS&E® systems protect high-threat facilities and help combat terrorism, trade fraud, drug smuggling, weapon smuggling, illegal immigration, and people smuggling.
BRUKER Corporation ( NasdaqGS: BRKR ) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial, diagnostics and applied analysis. CBRN (Chemical, biological, radiological, and nuclear defense) : The CBRNE threats facing Armed Forces, Emergency and Security Services across the globe are complex. Simple and reliable solutions are required in order to provide protection and fast, effective response. As the market leader in CBRNE for over 20 years, Bruker understand the threat and needs of those operating against it. Our trusted equipment and software is installed around the world providing unrivalled protection. Our equipment is always easy to use and enables full spectrum Detection, Identification and Monitoring utilising state of the art technology.
Cepheid ( NasdaqGS: CPHD ) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. BIOTHREATS : The Cepheid GeneXpert® System makes biothreat agent detection possible in minutes -- all from unprepared samples. This easy-to-use, automated and highly accurate real-time PCR instrument combines the ingenuity of more than 30 patents into a sophisticated genetic tool for first responders. A patented, disposable, cartridge test for anthrax is available now, and can be performed on-site -- delivering critical answers in critical situations.See the full stock directory here